| abstract |
Compounds of general formula (1), useful treatment or prevention of disorders related to nicotinic receptor dysfunction, especially at the CNS level. Claim 1: Compound that responds to the general formula (1), in which: R represents a C3-6 cycloalkyl group or a phenyl group optionally substituted by one or more groups chosen from a halogen atom, a C1-6 alkyl group , C1-6 alkoxy, nitro, amino, C1-3 dialkylamino, trifluoromethoxy, trifluoromethyl, cyano, hydroxy, methylenedioxy, or a piperidin-1-yl group, or 4-morpholinyl, or pyrrolidin-1-yl, or azetidin-1 -yl, or azepin-1-yl, or pyridinyl, or thienyl, opirazinyl, or furyl, or benzofuryl, or benzothienyl, or indolyl, or pyrimidinyl, or isoxazolyl, or phenoxazinyl, or dibenzofuryl or dibenzothienyl or pyrrolyl, or naphthyl, each of these groups will eventually be substituted by one or more groups chosen from a halogen atom, a C1-6 alkyl group, C1-6 alkoxy, trifluoromethoxy, trifluoromethyl, nitro, cyano, hydroxy, amino, C1-3 dialkylamino, or C3-8 cycloalkylamino, in the base or addition salt state with an acid. |